Matches in Wikidata for { <http://www.wikidata.org/entity/Q37390535> ?p ?o ?g. }
- Q37390535 description "article científic" @default.
- Q37390535 description "article scientifique" @default.
- Q37390535 description "articolo scientifico" @default.
- Q37390535 description "artigo científico" @default.
- Q37390535 description "artículu científicu espublizáu en 2009" @default.
- Q37390535 description "bilimsel makale" @default.
- Q37390535 description "scientific article published on 13 October 2009" @default.
- Q37390535 description "vedecký článok" @default.
- Q37390535 description "vetenskaplig artikel" @default.
- Q37390535 description "videnskabelig artikel" @default.
- Q37390535 description "vědecký článek" @default.
- Q37390535 description "wetenschappelijk artikel" @default.
- Q37390535 description "wissenschaftlicher Artikel" @default.
- Q37390535 description "наукова стаття, опублікована в жовтні 2009" @default.
- Q37390535 description "научни чланак" @default.
- Q37390535 description "مقالة علمية نشرت في 13 أكتوبر 2009" @default.
- Q37390535 name "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 name "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 name "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 type Item @default.
- Q37390535 label "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 label "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 label "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 prefLabel "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 prefLabel "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 prefLabel "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial." @default.
- Q37390535 P1433 Q37390535-ACF003B6-4181-455C-A537-4A35BA4D739C @default.
- Q37390535 P1476 Q37390535-6831B986-DB42-40EB-9056-1E11D770021B @default.
- Q37390535 P2093 Q37390535-08DF4FFE-52B2-4D98-BDF5-53459F30B8F9 @default.
- Q37390535 P2093 Q37390535-3B1D8DDA-B18C-4B32-BA3F-E1466238033C @default.
- Q37390535 P2093 Q37390535-3F46E4B9-FF96-4631-97AA-A1E7A94AE5D9 @default.
- Q37390535 P2093 Q37390535-5BBF6236-89C6-4D42-B22B-60BB572F355B @default.
- Q37390535 P2093 Q37390535-71DFBD44-8D17-4071-B9A7-04A40F1B67C4 @default.
- Q37390535 P2093 Q37390535-8D193BC8-48BD-46B1-BEFA-4DDD65D3474D @default.
- Q37390535 P2093 Q37390535-B68E9BB2-47C7-49A7-8614-D356D31F8F8D @default.
- Q37390535 P2093 Q37390535-B919DECF-A122-44DA-8E41-55B630D3B31E @default.
- Q37390535 P2093 Q37390535-D266EBF8-F0D7-431B-A2CF-951EF5EAA6A8 @default.
- Q37390535 P2093 Q37390535-E7B8EEA7-95A0-4C89-BD1C-DF24F9D34FA9 @default.
- Q37390535 P2093 Q37390535-E923075A-F3E0-4FA9-AEC2-5182A92AEAD4 @default.
- Q37390535 P2093 Q37390535-F5566B8E-27E1-4A03-A234-171E557BDD14 @default.
- Q37390535 P2093 Q37390535-F92D0F0F-F28B-4C03-AF42-9D2CA015CAD9 @default.
- Q37390535 P2860 Q37390535-0083D7E0-59DB-44E6-9C21-E05CBE2C959B @default.
- Q37390535 P2860 Q37390535-03B18A04-3FB5-44A7-94AA-1E58AC9C8345 @default.
- Q37390535 P2860 Q37390535-0E60A060-FFAB-4E7A-BC70-ADC04D699C28 @default.
- Q37390535 P2860 Q37390535-212B4DC0-0021-4363-A9CF-64286823A073 @default.
- Q37390535 P2860 Q37390535-249C3DB9-56FF-4CEC-9A0A-455536A0A219 @default.
- Q37390535 P2860 Q37390535-2D0694EC-332B-40C4-8502-B28B0EB68855 @default.
- Q37390535 P2860 Q37390535-2EA1D440-6701-4B30-AA3D-723E2C4737BA @default.
- Q37390535 P2860 Q37390535-341CE9F6-A21C-4F0C-8DFE-3526F61C6DAD @default.
- Q37390535 P2860 Q37390535-3C554B38-CAF9-425B-A734-D764BAAA4A10 @default.
- Q37390535 P2860 Q37390535-3F032F1A-5B91-4350-8F14-E6BB2FDB9741 @default.
- Q37390535 P2860 Q37390535-50983756-C214-4FEA-86BA-11C32EDF2698 @default.
- Q37390535 P2860 Q37390535-5894BEDC-85CF-4884-B18C-6AAE19C67C49 @default.
- Q37390535 P2860 Q37390535-5ED69768-EB7B-48C3-BAAF-9D06E167EE3E @default.
- Q37390535 P2860 Q37390535-61D51505-8C0A-4597-B10A-B7FA7C2CD059 @default.
- Q37390535 P2860 Q37390535-70A993EC-A280-4360-955D-249279BBCE2B @default.
- Q37390535 P2860 Q37390535-71F5A4DB-FF63-41EF-B4F1-262BEA339AD8 @default.
- Q37390535 P2860 Q37390535-7B6DCE02-DBCF-488C-B928-7DDC3989F1E9 @default.
- Q37390535 P2860 Q37390535-7F5D7F9A-EB50-482C-9D06-552E287B317D @default.
- Q37390535 P2860 Q37390535-8585F94C-25CF-45A4-A7CE-D33A52B59438 @default.
- Q37390535 P2860 Q37390535-8C7FB285-20A8-402F-9A61-BDEB88F21379 @default.
- Q37390535 P2860 Q37390535-916BAAC1-383C-457D-996E-BEAEBC3E09D6 @default.
- Q37390535 P2860 Q37390535-9852FBD3-4FDD-4672-8B1F-480A93500BF7 @default.
- Q37390535 P2860 Q37390535-9A4C2F8A-7443-4EE9-BE8A-43DB799665CD @default.
- Q37390535 P2860 Q37390535-9CD97050-1A20-4210-B9CC-93BBFEDEB011 @default.
- Q37390535 P2860 Q37390535-9EAA5250-BD5A-442B-8CA8-641F1AFDAA07 @default.
- Q37390535 P2860 Q37390535-A3E86BBB-0B79-4927-B817-AB7562C91F54 @default.
- Q37390535 P2860 Q37390535-A92E687A-7F7F-4381-A8B6-B894D15BC777 @default.
- Q37390535 P2860 Q37390535-AACAF98B-90F7-4ABA-9D1C-60D5238DCED5 @default.
- Q37390535 P2860 Q37390535-AC517F11-09D2-4B6E-9F17-C327DE03E84C @default.
- Q37390535 P2860 Q37390535-B92BD149-DF27-4B53-9F05-C38A726091DF @default.
- Q37390535 P2860 Q37390535-CFB6C428-9EA0-4467-A839-EF1C0E987256 @default.
- Q37390535 P2860 Q37390535-DAE0354D-2455-47A1-AECD-7A71DE6C082E @default.
- Q37390535 P2860 Q37390535-DD0D6B0B-CE8E-455F-A90D-1E45FEF0CCC5 @default.
- Q37390535 P2860 Q37390535-E367CEC3-BF82-4585-9BC3-77C542E7D07B @default.
- Q37390535 P2860 Q37390535-E492EE56-FAE7-4C83-8880-1CB5FC39D002 @default.
- Q37390535 P2860 Q37390535-F75A0107-E13D-47F3-8457-28B8AC1C2041 @default.
- Q37390535 P2860 Q37390535-F7E27E8F-AA26-49A7-89A0-0043B6E0EA76 @default.
- Q37390535 P2860 Q37390535-FC45EA9F-B6FF-40DD-BD64-13C132FBAD1D @default.
- Q37390535 P304 Q37390535-520B60A3-B149-4A35-8D1B-C14C4FB39400 @default.
- Q37390535 P31 Q37390535-82F1D5AF-44E5-45CD-B078-25F54B696C5E @default.
- Q37390535 P356 Q37390535-1283CF4B-17FA-414F-BBD1-BE5F920A24C2 @default.
- Q37390535 P407 Q37390535-990CBF13-41FD-4E54-B76F-6AC1ACF04C45 @default.
- Q37390535 P433 Q37390535-905A55F9-F04A-4816-9EB7-FDF4F4D16BF5 @default.
- Q37390535 P478 Q37390535-B5540701-2DFA-45EC-90F2-FC6A2356050F @default.
- Q37390535 P50 Q37390535-4466B7AD-9476-4C41-81AB-5DA72AADE85B @default.
- Q37390535 P50 Q37390535-F56C0508-F9F7-4E53-8FC8-439C91587464 @default.
- Q37390535 P577 Q37390535-BF4CBBD9-09AA-4781-B51C-64E83D1316C5 @default.
- Q37390535 P5875 Q37390535-BDDF5698-87F1-4164-A6AB-67A990259D39 @default.
- Q37390535 P698 Q37390535-42523B21-2261-4C06-B48D-5F0FE1E38A1C @default.
- Q37390535 P921 Q37390535-C5804200-3B09-49EA-A981-BADE44BF4C9B @default.
- Q37390535 P932 Q37390535-13939FA5-C135-41FE-A862-D5933F530AE2 @default.
- Q37390535 P356 1078-0432.CCR-09-0905 @default.
- Q37390535 P698 19825958 @default.
- Q37390535 P1433 Q332253 @default.
- Q37390535 P1476 "The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial" @default.
- Q37390535 P2093 "Borko D Jovanovic" @default.
- Q37390535 P2093 "Daina Variakojis" @default.
- Q37390535 P2093 "David Patton" @default.
- Q37390535 P2093 "Elizabeth Hamilton" @default.